Insider filing · ZBIO

Fairmount Funds Management LLC bought $6.0M of Zenas BioPharma (ZBIO)

Executed Oct 7 2025, disclosed Oct 9 2025, 2 days later.

Over the 21 trading sessions from the disclosed entry session (Oct 9 2025), the stock returned +23.8% (delay-adjusted); from the execution session (Oct 7 2025), +30.0%. Derived: entry at the session's open, exit at the close 20 sessions later.

FL Fairmount Funds Management LLC Director profile →

Fairmount Funds Management LLC (Director) filed 10 Form 4 reports as a reporting entity in the trailing twelve months (6 purchases, 4 sales), most often in Cogent Biosciences, Inc. (COGT). Across 6 priced purchase filings, the average 21-session return was +5.9% from execution and +8.5% from disclosure (delay-adjusted; derived). The largest single filing was $399.7M of SYRE (4,684,781 sh × $85.31, as filed), executed Jun 23.

ZBIO Zenas BioPharma, Inc. ZBIO · Healthcare · 18 filings in 24 months ticker →

Healthcare · Zenas BioPharma, Inc., a clinical-stage biopharma company, engages in the development and commercialization of transformative immunology-ba…

More Healthcare filings→ Insider filings, newest first→ View the original filing at www.sec.gov→